According to the Finance and Economics App, Zhejiang Jingxin Pharmaceutical (002020.SZ) released the third quarter report for 2024. In the first three quarters, the company achieved revenue of 3.209 billion yuan, a year-on-year increase of 9.68%. The net income attributable to the shareholders of the listed company was 0.575 billion yuan, an increase of 21.66% year-on-year. The net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.494 billion yuan, an increase of 13.16% year-on-year.